<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04092309</url>
  </required_header>
  <id_info>
    <org_study_id>ACE_SAVA_3Decho_BMT</org_study_id>
    <nct_id>NCT04092309</nct_id>
  </id_info>
  <brief_title>Effect of Angiotensin Converting Enzyme and Sacubitril Valsartan in Patients After Bone Marrow Transplantation</brief_title>
  <official_title>Effect of Angiotensin Converting Enzyme and Sacubitril Valsartan in Left Atrial and Left Ventricular Performance, as Assessed With 3D Echocardiography, in Patients After Bone Marrow Transplantation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Athens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present study is to investigate the effect of ACE inhibitors and the
      sacubitril-valsartan complex in bone marrow transplant patients by assessing cardiovascular
      and endothelial parameters in order to search for a potent protective role.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the present study is to investigate the effect of ACE inhibitors and the
      sacubitril-valsartan complex in bone marrow transplant patients in preventing cardiotoxicity
      when administered immediately after transplantation.

      The effect of medication will be studied in detail:

      i) in global longitudinal strain of left ventricle (GLS), ii) in the volume change of the
      right and the left ventricle, through the cardiac cycle using 3D echocardiography, iii) in
      the Myocardial Work Index (MWI) of the left ventricle, with a strain -pressure curve study
      iv) in the 4D strain of the left atrium, v) in elastic properties of aorta (pulse wave
      velocity (PWV), central systolic pressure (CSBP-mmHg) and augmentation index (Aix%), vii) in
      permeability of glycocalyx and viii) in serum biomarker values, namely troponin I high
      sensitivity and atrial natriuretic peptide (NT-proBNP).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>one group after bone marrow transpalntation treated with ACE one group after bone marrow transpalntation treated with sacubitril-valsartan one group after bone marrow transpalntation treated with none of these (control group)</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of treatment in Left Ventricular Function</measure>
    <time_frame>2 years</time_frame>
    <description>Left Ventricular Function is assessed by calculating Ejection fraction by 3D echocardiography.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of treatment in left ventricular function</measure>
    <time_frame>2 years</time_frame>
    <description>Left Ventricular function is assessed by Global Longitudinal Strain by speckle tracking echocardiography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of treatment in arterial stiffness</measure>
    <time_frame>2 years</time_frame>
    <description>Arterial Stiffness is evaluated by Pulse Wave Velocity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of treatment in glycocalyx thickness</measure>
    <time_frame>2 years</time_frame>
    <description>Glycocalyx thickness is assessed by measuring perfused boundary region (PBR) of the sublingual arterial microvessels (range 5-25 Âµm</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Hematopoietic Stem Cell Transplantation</condition>
  <condition>Cardiotoxicity</condition>
  <arm_group>
    <arm_group_label>ACE group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients after bone marrow transplantation will be treated with ACE inhibitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sacubitril Valsartan group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients after bone marrow transplantation will be treated with sacubitril valsartan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients after bone marrow transplantation will be treated neither with ACE i nor with sacubitril valsartan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACE inhibitor, Sacubitril-Valsartan</intervention_name>
    <description>Search for Protective effect after chemotherapy and bone marrow transplantation</description>
    <arm_group_label>ACE group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Sacubitril Valsartan group</arm_group_label>
    <other_name>Sacubitril-Valsartan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adolescents male and female

          -  that have just been treated with bone marrow transplantation due to haematological
             malignancies.

        Exclusion Criteria:

          -  Coronary Artery Disease

          -  Permanent Atrial Fibrilation

          -  Signs of Left Ventricular Hypertrophy on electrocardiography or echocardiography

          -  Left ventricle Ejection Fraction&lt;50% or segmental wall motion abnormalities of left
             ventricle

          -  More than moderate valvular disease

          -  Primary Myocardiopathy

          -  Blood Pressure&lt;90 mmHg

          -  GFR&lt;30 ml/min/1,73m2

          -  Unwilling to recruit

          -  Uncontrolled Arterial hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ignatios Ikonomidis, Assoc. Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Athens University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ignatios Ikonomidis, Assoc.Prof.</last_name>
    <phone>+30 2105832192</phone>
    <email>ignoik@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Konstantinos Katogiannis, Fellow</last_name>
    <phone>+30 2105832192</phone>
    <email>kenndj89@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>&quot;Attikon&quot; University General Hospital</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ignatios Ikonomidis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 14, 2019</study_first_submitted>
  <study_first_submitted_qc>September 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2019</study_first_posted>
  <last_update_submitted>April 1, 2020</last_update_submitted>
  <last_update_submitted_qc>April 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Athens</investigator_affiliation>
    <investigator_full_name>Ignatios Ikonomidis</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Cardio-oncology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>LCZ 696</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

